Erik Håkansson

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Peritoneal Dialysis

Chronic Kidney Disease

Clinical Practice

Acute Heart Failure

Top Venues

European journal of clinical pharmacology

Cardiovascular therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Helena Norberg, Therese Andersson, Erik Håkansson, Karin Hellström Ängerud, Krister Lindmark
Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin. European journal of clinical pharmacology (2024)
Helena Norberg, Therese Andersson, Erik Håkansson, Karin Hellström Ängerud, Krister Lindmark
Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin. European journal of clinical pharmacology 80 (9) (2024)
Helena Norberg, Therese Andersson, Erik Håkansson, Karin Hellström Ängerud, Krister Lindmark
Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin. European journal of clinical pharmacology 80 (9) (2024)
Helena Norberg, Therese Andersson, Erik Håkansson, Karin Hellström Ängerud, Krister Lindmark
Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin. European journal of clinical pharmacology 80 (9) (2024)
Erik Håkansson, Mattias Brunström, Helena Norberg, Sara Själander, Krister Lindmark
Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure population: a single-centre cross-sectional study. Open heart 9 (2) (2023)
Erik Håkansson, Mattias Brunström, Helena Norberg, Sara Själander, Krister Lindmark
Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure population: a single-centre cross-sectional study. Open heart 9 (2) (2023)
Erik Håkansson, Helena Norberg, Sara Själander, Krister Lindmark
Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population. Cardiovascular therapeutics 2021 (2021)